title: FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive?
authors.affiliation: BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERehd, Spain.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Liccioni
authors.affiliation: BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERehd, Spain.
authors.forename: Maria
authors.initials: M
authors.lastname: Reig
authors.affiliation: BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERehd, Spain. Electronic address: jbruix@clinic.ub.es.
authors.forename: Jordi
authors.initials: J
authors.lastname: Bruix
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D010166:Palliative Care
keywords: BCLC; HCC; Treatment